|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **TB** | **PSR** | **AB** | **OPN** | **ONC** | **OCC** |
| **P-CTR** | 100±24.63% | 100±32.63% | 100±27.97% | 100±23.79% | 100±61.16% | 100±31.46% |
| **N-CTR** | 127.63±98.36% | 114.51±53.71% | 110.44±17.20% | 18.22±1.44% | 23.91±8.29% | 35.79±11.46% |
| **BP** | 293.75±39.72% | 138.63±25.85% | 206.83±11.59% | 11.40±9.31% | 17.36±8.35% | 12.92±3.03% |
| **HOLO** | 318.09±55.24% | 120.38±29.58% | 118.47±36.59% | 29.12±6.02% | 120.69±76.94% | 214.02±47.73% |
| **P-CTR vs. N-CTR *p* value** | 0.7435 | 0.8173 | 0.7919 | <0.0001\* | 0.0078\* | 0.0001\* |
| **P-CTR vs. BP *p* value** | <0.0001\* | 0.1098 | <0.0001\* | <0.0001\* | 0.0035\* | <0.0001\* |
| **P-CTR vs. HOLO *p* value** | <0.0001\* | 0.6123 | 0.3720 | <0.0001\* | 0.7866 | <0.0001\* |
| **N-CTR vs. BP *p* value** | <0.0001\* | 0.4743 | <0.0001\* | 0.6556 | 0.9908 | 0.3125 |
| **N-CTR vs. HOLO *p* value** | <0.0001\* | 0.9845 | 0.8920 | 0.2650 | 0.0006\* | <0.0001\* |
| **BP vs. HOLO *p* value** | 0.8093 | 0.6911 | <0.0001\* | 0.0232\* | 0.0002\* | <0.0001\* |

**Supplementary Table 2. Quantitative histochemical and immunohistochemical analysis of the animals included in the study.** P-CTR: positive control of native, non-operated animals; N-CTR: negative control animals in which the bone defect was not filled by any grafted material; BP: animals in which the bone defect was filled with commercially available bone mineral particles (BP) used clinically; HOLO: animals in which the bone defect was filled with HOLO particles. TB, toluidine blue; PSR, picrosirius red; AB, alcian blue; OPN, osteopontin; ONC, osteonectin; OCC, osteocalcin. Values in the top rows correspond to average cell viability levels normalized to positive and negative controls. Values shown in the lower rows correspond to statistical p values for the comparison of results obtained in two specific groups. Statistically significant differences are highlighted with asterisks (\*).